MCID: ACT135
MIFTS: 56

Acute Graft Versus Host Disease

Categories: Rare diseases, Blood diseases, Genetic diseases

Aliases & Classifications for Acute Graft Versus Host Disease

MalaCards integrated aliases for Acute Graft Versus Host Disease:

Name: Acute Graft Versus Host Disease 53 59
Acute Graft-Versus-Host Disease 55
Acute Gvh Disease 73
Acute Gvhd 53

Classifications:

Orphanet: 59  
Rare immunological diseases


External Ids:

Orphanet 59 ORPHA99920
ICD10 via Orphanet 34 T86.0
UMLS via Orphanet 74 C0856825
UMLS 73 C0856825

Summaries for Acute Graft Versus Host Disease

MalaCards based summary : Acute Graft Versus Host Disease, also known as acute graft-versus-host disease, is related to hematopoietic stem cell transplantation and chronic graft versus host disease. An important gene associated with Acute Graft Versus Host Disease is ARHGAP45 (Rho GTPase Activating Protein 45), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Vidarabine and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Acute Graft Versus Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Acute Graft Versus Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 265)
# Related Disease Score Top Affiliating Genes
1 hematopoietic stem cell transplantation 30.8 ARHGAP45 IFNG IL10 IL2 TNF
2 chronic graft versus host disease 30.8 IFNG IL10 IL2RA
3 mouth disease 30.5 IFNG IL10 TNF
4 aspergillosis 30.4 IFNG IL10 IL4
5 combined immunodeficiency, x-linked 30.2 IL2 IL2RA IL4
6 cytomegalovirus infection 30.1 IFNG IL10 IL2RA TNF
7 bronchiolitis 30.0 IFNG IL10 IL4 TNF
8 lymphopenia 29.6 FASLG IFNG IL2 IL2RA
9 bronchiolitis obliterans 29.5 GZMB IFNG IL10 TNF
10 graft-versus-host disease 29.5 ARHGAP45 FASLG GZMB IFNG IL10 IL2
11 lichen planus 29.3 GZMB IFNG IL4 TNF
12 colitis 28.8 IFNG IL10 IL2 IL4 NOD2 TNF
13 erythema multiforme 28.6 FASLG GZMB IFNG IL2 TNF
14 punctate inner choroidopathy 10.9 IL10 TNF
15 oral tuberculosis 10.8 IL2 TNF
16 variola major 10.8 IFNG IL2
17 microscopic polyangiitis 10.8 IL10 TNF
18 mycoplasmal pneumonia 10.8 IFNG IL4
19 multifocal choroiditis 10.8 IL10 TNF
20 staphylococcal toxic shock syndrome 10.8 IFNG TNF
21 fixed drug eruption 10.8 IFNG IL2
22 berylliosis 10.8 IFNG IL2
23 sporotrichosis 10.8 IFNG IL10
24 transient hypogammaglobulinemia 10.8 IL10 TNF
25 virus associated hemophagocytic syndrome 10.7 IL2 IL4
26 streptococcal toxic-shock syndrome 10.7 IL2 TNF
27 trichosporonosis 10.7 IFNG TNF
28 immunoglobulin a deficiency 1 10.7 IL10 IL4
29 chronic beryllium disease 10.7 IFNG TNF
30 choroiditis 10.7 IL10 TNF
31 farmer's lung 10.7 IL2 TNF
32 b-cell growth factor 10.7 IFNG IL4
33 systemic onset juvenile idiopathic arthritis 10.7 IL18 TNF
34 retinitis pigmentosa 22 10.7 IL10 IL4
35 necrotizing ulcerative gingivitis 10.7 IL10 IL18
36 penicillin allergy 10.6 IFNG IL4
37 idiopathic achalasia 10.6 IL10 TNF
38 pouchitis 10.6 IL10 NOD2
39 chronic active epstein-barr virus infection 10.6 IFNG IL10 IL2
40 granulomatous dermatitis 10.6 NOD2 TNF
41 jak3-deficient severe combined immunodeficiency 10.6 IL2 IL4
42 hemorrhagic fever 10.6 IFNG IL10 TNF
43 herpes zoster 10.6 IFNG IL10 IL2
44 spotted fever 10.6 IFNG IL10 TNF
45 aseptic meningitis 10.6 IFNG IL10 TNF
46 autoimmune myocarditis 10.6 IFNG IL2 TNF
47 plasmodium vivax malaria 10.6 IFNG IL10 TNF
48 cow milk allergy 10.6 IL10 IL18
49 trichuriasis 10.6 IL10 TNF
50 mixed connective tissue disease 10.6 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Acute Graft Versus Host Disease:



Diseases related to Acute Graft Versus Host Disease

Symptoms & Phenotypes for Acute Graft Versus Host Disease

GenomeRNAi Phenotypes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 NOD2 TNF GZMB IL10 IL18 IL2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 NOD2 TNF FASLG GZMB IL10 IL18

MGI Mouse Phenotypes related to Acute Graft Versus Host Disease:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 NOD2 TNF IL4 MYH9 IL2 IL10
2 digestive/alimentary MP:0005381 10.21 IL2RA NOD2 TNF IL4 TNFRSF4 IL10
3 hematopoietic system MP:0005397 10.2 IL2RA NOD2 TNF IL4 MYH9 TNFRSF4
4 growth/size/body region MP:0005378 10.18 MYH9 IL2RA NOD2 TNF IL4 IL2
5 homeostasis/metabolism MP:0005376 10.17 NOD2 IL2RA TNF IL4 MYH9 IL2
6 immune system MP:0005387 10.14 IL2RA NOD2 TNF IL4 TNFRSF4 MYH9
7 endocrine/exocrine gland MP:0005379 10.04 IL2 IL2RA TNF IL4 IFNG IL10
8 mortality/aging MP:0010768 10 MYH9 IL2RA NOD2 TNF IL4 IL2
9 integument MP:0010771 9.91 TNF IL4 IL10 FASLG IL18 IFNG
10 liver/biliary system MP:0005370 9.87 TNF IL4 IL2 IL10 FASLG IFNG
11 no phenotypic analysis MP:0003012 9.63 MYH9 TNF IL4 IL2 IL10 IFNG
12 respiratory system MP:0005388 9.56 IL2RA TNF IL4 TNFRSF4 IL10 FASLG
13 vision/eye MP:0005391 9.28 IL2RA TNF IL4 MYH9 IL10 FASLG

Drugs & Therapeutics for Acute Graft Versus Host Disease

Drugs for Acute Graft Versus Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 363)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
3
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
4
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
5
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 147-94-4 6253
6
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 152923-56-3, 179045-86-4
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
8
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
9
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
10
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 104987-11-3 445643 439492
11
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
12
Lomustine Approved, Investigational Phase 4,Not Applicable 13010-47-4 3950
13
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 128794-94-5 5281078
14
Foscarnet Approved Phase 4,Not Applicable 63585-09-1, 4428-95-9 3415
15
Infliximab Approved Phase 4,Phase 2,Phase 1 170277-31-3
16
Ganciclovir Approved, Investigational Phase 4,Not Applicable 82410-32-0 3454
17
Menthol Approved Phase 4,Phase 1,Phase 2,Not Applicable 2216-51-5 16666
18
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
19
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
20
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
22
Treosulfan Investigational Phase 4,Phase 2,Phase 3,Phase 1 299-75-2 9296
23 Semustine Experimental, Investigational Phase 4,Not Applicable 13909-09-6
24
Phosphonoacetic Acid Experimental Phase 4,Not Applicable 4408-78-0 546
25
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
26 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Folic Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
33 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
34 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
38 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
42 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
43 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1,Not Applicable
46 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 823)
# Name Status NCT ID Phase Drugs
1 ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
2 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
3 Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation Fro Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
4 Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT Completed NCT01232504 Phase 4 rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
5 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Recruiting NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
6 Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Recruiting NCT02677181 Phase 4 ATG;CsA;mycophenolate mofetil;Methotrexate
7 Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT Recruiting NCT02634294 Phase 4 Peg interferon alfa-2b
8 Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors Recruiting NCT02412423 Phase 4 post-transplantation cyclophosphamide
9 Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis Recruiting NCT01856803 Phase 4 anti thymoglobulin
10 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
11 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
12 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
13 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4 Busulfan;Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Tacrolimus;Methotrexate;Thymoglobulin;Basiliximab
14 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
15 A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT Not yet recruiting NCT03190733 Phase 4 ATG
16 Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation Not yet recruiting NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG(Sanofi/Genzyme)
17 Extracorporeal Photopheresis for Acute Graft Versus Host Disease Unknown status NCT00179855 Phase 2, Phase 3
18 MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis Unknown status NCT02270307 Phase 2, Phase 3 Cyclophosphamide
19 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
20 Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3 filgrastim
21 Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia Unknown status NCT01145976 Phase 3 Cy-ATG;Flu-ATG
22 P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies Unknown status NCT01854567 Phase 3
23 Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Unknown status NCT01295710 Phase 3
24 The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
25 The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease Completed NCT00726375 Phase 3 Etanercept (Enbrel)
26 Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease Completed NCT00035880 Phase 2, Phase 3 ABX-CBL
27 Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease Completed NCT00929695 Phase 3 prednisone;methylprednisolone
28 Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD Completed NCT00562497 Phase 3 Prochymal
29 Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease Completed NCT00366145 Phase 3
30 Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT) Completed NCT00655343 Phase 3 ATG-Fresenius S
31 Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease Completed NCT00053976 Phase 3 methylprednisolone;Placebo
32 A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD Completed NCT02336230 Phase 3 remestemcel-L
33 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
34 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
35 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
36 Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation Completed NCT00130754 Phase 3 Thymoglobuline
37 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
38 Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease Completed NCT01788501 Phase 2, Phase 3 Tacrolimus;Cyclosporine;Methotrexate
39 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
40 Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation Completed NCT00002456 Phase 3 cyclosporine;methotrexate
41 Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation Completed NCT00993343 Phase 3 Sirolimus/tacrolimus;cyclosporine/methotrexate
42 Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies Completed NCT00275678 Phase 3
43 Nonmyeloablative Stem Cell Transplant in Elderly Completed NCT00382759 Phase 2, Phase 3
44 Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
45 Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA Completed NCT00455312 Phase 2, Phase 3 Campath 1H;Cyclophosphamide;Fludarabine;antithymocyte globulin;Methylprednisolone
46 Stem Cell Transplant for Bone Marrow Failure Syndromes Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
47 Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy Completed NCT00469729 Phase 2, Phase 3 StemEx®
48 Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients Completed NCT00411645 Phase 3 maribavir
49 Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) Completed NCT00412360 Phase 3 Cyclophosphamide;Fludarabine;Cyclosporine A;Mycophenolate Mofetil
50 Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Completed NCT00928018 Phase 3 Sirolimus;Methotrexate;Tacrolimus;Cyclosporine;MMF

Search NIH Clinical Center for Acute Graft Versus Host Disease

Genetic Tests for Acute Graft Versus Host Disease

Anatomical Context for Acute Graft Versus Host Disease

MalaCards organs/tissues related to Acute Graft Versus Host Disease:

41
T Cells, Bone, Bone Marrow, Myeloid, Nk Cells, Skin, B Cells

Publications for Acute Graft Versus Host Disease

Articles related to Acute Graft Versus Host Disease:

(show top 50) (show all 787)
# Title Authors Year
1
Mesenchymal stem cells transplantation in hematological patients with acute graft-versus-host disease: characteristics and risk factors for infectious complications. ( 29380038 )
2018
2
Change of apheresis device decreased the incidence of severe acute graft-versus-host disease among patients after allogeneic stem cell transplantation with sibling donors. ( 29536557 )
2018
3
TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells. ( 29960041 )
2018
4
The glucocorticoid receptor in recipient cells keeps cytokine secretion in acute graft-versus-host disease at bay. ( 29643984 )
2018
5
Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. ( 29345306 )
2018
6
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft versus host disease: low incidence of lower gastrointestinal tract disease. ( 29351985 )
2018
7
Photopheresis of a less than 10-kg child with acute graft versus host disease accompanied with hyperbilirubinemia: A case report. ( 29778715 )
2018
8
The Therapeutic Effect of ICAM-1-Overexpressing Mesenchymal Stem Cells on Acute Graft-Versus-Host Disease. ( 29763906 )
2018
9
MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. ( 29720426 )
2018
10
Simple, Reproducible, and Efficient Clinical Grading System for Murine Models of Acute Graft-versus-Host Disease. ( 29403494 )
2018
11
Plasma vascular non-inflammatory molecule 3 is associated with gastrointestinal acute graft-versus-host disease in mice. ( 29311761 )
2018
12
Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study. ( 29755674 )
2018
13
Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: a single-center experience. ( 29707788 )
2018
14
Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter? ( 29446444 )
2018
15
18F-3'-deoxy-3'-fluorothymidine (FLT) PET imaging for the prediction of acute graft-versus-host disease in mouse hematopoietic stem cell transplant models. ( 29981461 )
2018
16
Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival. ( 29391524 )
2018
17
Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. ( 29684567 )
2018
18
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). ( 29379171 )
2018
19
Vedolizumab for treatment of steroid-refractory lower gastrointestinal acute graft-versus-host disease. ( 29371686 )
2018
20
Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis. ( 29795434 )
2018
21
Acute Graft-versus-Host Disease. ( 29419277 )
2018
22
Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease <i>via</i> the Treg/Th17 Balance in Allo-HSCT Recipients. ( 29740427 )
2018
23
Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. ( 29795429 )
2018
24
Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients. ( 29667720 )
2018
25
Regulatory I^I' T cells induced by G-CSF participate in acute graft-versus-host disease regulation in G-CSF-mobilized allogeneic peripheral blood stem cell transplantation. ( 29801459 )
2018
26
Association analysis between SUFU polymorphism rs17114808 and acute graft versus host disease after hematopoietic stem cell transplantation. ( 29330404 )
2018
27
Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients. ( 29427741 )
2018
28
Acute Graft-versus-Host Disease. ( 29414273 )
2018
29
Prediction of absolute risk of acute graft-versus-host disease following hematopoietic cell transplantation. ( 29346409 )
2018
30
CXCR3 blockade combined with cyclosporine A alleviates acute graft-versus-host disease by inhibiting alloreactive donor T cell responses in a murine model. ( 29288898 )
2018
31
MicroRNA in T-Cell Development and T-Cell Mediated Acute Graft-Versus-Host Disease. ( 29867969 )
2018
32
Extracorporeal photopheresis is a valuable treatment option in steroid-refractory or steroid-dependent acute graft versus host disease-experience with three different approaches. ( 29907805 )
2018
33
I+<sub>1</sub>-Antitrypsin Infusion for treatment of Steroid Resistant Acute Graft-versus-Host Disease. ( 29437593 )
2018
34
Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation. ( 29800615 )
2018
35
Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. ( 29670210 )
2018
36
Acute graft-versus-host disease following lung transplantation in a patient with a novel<i>TERT</i>mutation. ( 29382801 )
2018
37
Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation. ( 29582333 )
2018
38
Acute graft-versus-host disease of the gut: considerations for the gastroenterologist. ( 28951581 )
2017
39
Correction: Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. ( 28938702 )
2017
40
Bridging-to-transplant with Azacitidine for Myelodysplastic Syndrome and Acute Myeloid Leukemia, Reduces the Incidence of Acute Graft-versus-host Disease. ( 28670436 )
2017
41
Predicting death in patients with acute graft-versus-host disease after reduced-intensity conditioning. ( 28863797 )
2017
42
Cutaneous acute graft-versus-host disease with isomorphic disposition over striae distensae in a 12-year-old girl. ( 27805255 )
2017
43
Peripheral blood Th9 cells reconstitution and its relationship with acute graft-versus-host disease after matched-sibling peripheral blood hematopoietic stem cell transplantation. ( 28861153 )
2017
44
Dynamics of M1 macrophages in oral mucosal lesions during the development of acute graft-versus-host disease in rats. ( 28862740 )
2017
45
CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study. ( 28131632 )
2017
46
The association between acute graft-versus-host disease and antimicrobial peptide expression in the gastrointestinal tract after allogeneic stem cell transplantation. ( 28934349 )
2017
47
Lessons Learned from Early Experiences with Vedolizumab for Steroid-Refractory Acute Graft- versus-Host Disease with Gastrointestinal Involvement. ( 28578009 )
2017
48
Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. ( 28423578 )
2017
49
Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. ( 28088653 )
2017
50
Changes in body composition in children with acute graft-versus-host disease within the first 100 days after hematopoietic stem cell transplantation. ( 29269889 )
2017

Variations for Acute Graft Versus Host Disease

Expression for Acute Graft Versus Host Disease

Search GEO for disease gene expression data for Acute Graft Versus Host Disease.

Pathways for Acute Graft Versus Host Disease

Pathways related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 ARHGAP45 FASLG IFNG IL10 IL18 IL2
2
Show member pathways
13.8 FASLG IL10 IL18 IL2 IL2RA IL4
3
Show member pathways
13.66 FASLG IFNG IL10 IL18 IL2 IL2RA
4
Show member pathways
13.47 IFNG IL10 IL18 IL2 IL2RA IL4
5
Show member pathways
13.4 FASLG IL10 IL18 IL2 IL2RA IL4
6
Show member pathways
13.33 FASLG IFNG IL10 IL18 IL2 IL2RA
7
Show member pathways
13.27 FASLG IL10 IL18 IL2 IL2RA IL4
8
Show member pathways
13.03 FASLG IFNG IL10 IL18 IL2 NOD2
9
Show member pathways
12.94 FASLG IL2 IL2RA IL4 TNF
10
Show member pathways
12.85 FASLG GZMB IFNG IL10 IL18 IL2
11 12.82 FASLG IFNG IL2 IL2RA IL4
12
Show member pathways
12.8 FASLG IFNG IL18 IL2 IL2RA IL4
13
Show member pathways
12.78 IFNG IL2 IL2RA IL4 TNF
14
Show member pathways
12.68 IFNG IL10 IL18 IL2 IL2RA IL4
15
Show member pathways
12.6 IFNG IL10 IL18 IL2 TNF
16
Show member pathways
12.56 FASLG GZMB IFNG IL2 IL4 TNF
17
Show member pathways
12.46 IFNG IL10 IL2 IL4 TNF
18
Show member pathways
12.39 IFNG IL10 IL18 IL2 IL2RA IL4
19
Show member pathways
12.33 IFNG IL2 IL4 TNF
20 12.32 FASLG GZMB IFNG IL10 IL2 IL2RA
21
Show member pathways
12.31 IFNG IL10 IL18 IL2 TNF
22 12.29 IFNG IL10 IL18 NOD2 TNF
23
Show member pathways
12.26 IFNG IL10 IL4 TNF
24
Show member pathways
12.19 FASLG IFNG IL4 TNF
25
Show member pathways
12.16 FASLG GZMB TNF
26
Show member pathways
12.12 IFNG IL10 IL18 IL2 IL2RA IL4
27 12.05 IFNG IL2 IL4 TNF
28 12.05 FASLG IL10 IL18 IL4 TNF
29 12.05 IFNG IL10 IL2 IL2RA IL4 TNF
30
Show member pathways
12.02 IFNG IL2 IL2RA
31 11.92 IFNG IL10 IL2 IL2RA
32 11.88 IL2RA IL4 TNF
33 11.87 IFNG IL10 TNF
34
Show member pathways
11.85 FASLG GZMB IFNG IL18 IL2 IL2RA
35 11.84 IFNG IL18 TNF
36 11.82 IFNG IL18 MYH9
37 11.82 IFNG IL10 IL2 TNF
38 11.79 IFNG IL2 IL4
39
Show member pathways
11.77 FASLG IL2 IL2RA IL4
40
Show member pathways
11.76 FASLG IFNG IL2 IL2RA IL4 TNF
41
Show member pathways
11.67 IFNG IL2 TNF
42 11.63 FASLG IFNG IL2 TNF
43 11.61 IL10 IL18 IL4 TNF
44 11.6 IFNG IL10 IL18 TNF
45 11.54 IFNG IL2 TNF
46 11.54 IFNG IL18 TNF
47 11.51 FASLG IFNG TNF
48 11.46 IFNG IL10 IL2 IL2RA IL4 TNFRSF4
49 11.44 FASLG IFNG IL10 IL18 TNF
50 11.4 IFNG IL2 IL2RA IL4

GO Terms for Acute Graft Versus Host Disease

Cellular components related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 FASLG IFNG IL10 IL18 IL2 IL4
2 cell surface GO:0009986 9.35 FASLG IL2RA NOD2 TNF TNFRSF4
3 extracellular region GO:0005576 9.23 ARHGAP45 FASLG IFNG IL10 IL18 IL2

Biological processes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.95 IL18 IL2 IL2RA TNF
2 tumor necrosis factor-mediated signaling pathway GO:0033209 9.85 FASLG TNF TNFRSF4
3 apoptotic signaling pathway GO:0097190 9.83 FASLG TNF TNFRSF4
4 cellular response to organic cyclic compound GO:0071407 9.81 IL18 NOD2 TNF
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 IFNG IL18 IL2
6 inflammatory response GO:0006954 9.8 IL10 IL18 IL2RA NOD2 TNF TNFRSF4
7 positive regulation of T cell proliferation GO:0042102 9.79 IL2 IL2RA IL4
8 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.76 IL18 NOD2 TNF
9 negative regulation of inflammatory response GO:0050728 9.76 IL10 IL2 IL2RA NOD2
10 extrinsic apoptotic signaling pathway GO:0097191 9.74 FASLG IFNG TNF
11 positive regulation of interferon-gamma production GO:0032729 9.73 IL18 IL2 TNF
12 positive regulation of B cell proliferation GO:0030890 9.72 IL2 IL4 TNFRSF4
13 regulation of signaling receptor activity GO:0010469 9.7 FASLG IFNG IL10 IL18 IL2 IL4
14 positive regulation of protein complex assembly GO:0031334 9.69 IFNG TNF
15 negative regulation of myoblast differentiation GO:0045662 9.69 IL18 TNF
16 natural killer cell activation GO:0030101 9.68 IL18 IL2
17 natural killer cell mediated cytotoxicity GO:0042267 9.68 GZMB IL18
18 positive regulation of osteoclast differentiation GO:0045672 9.68 IFNG TNF
19 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.67 IFNG TNF
20 negative regulation of growth of symbiont in host GO:0044130 9.67 IL10 TNF
21 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL10 TNF
22 positive regulation of immunoglobulin secretion GO:0051024 9.66 IL2 TNFRSF4
23 interleukin-2-mediated signaling pathway GO:0038110 9.66 IL2 IL2RA
24 positive regulation of isotype switching to IgG isotypes GO:0048304 9.65 IL2 IL4
25 positive regulation of activated T cell proliferation GO:0042104 9.65 IL18 IL2 IL2RA
26 endothelial cell apoptotic process GO:0072577 9.64 IL10 TNF
27 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 IL10 IL4
28 negative regulation of cytokine secretion involved in immune response GO:0002740 9.61 IL10 TNF
29 negative regulation of lymphocyte proliferation GO:0050672 9.61 IL2 IL2RA
30 positive regulation of T cell differentiation GO:0045582 9.61 IL2 IL2RA IL4
31 necroptotic signaling pathway GO:0097527 9.6 FASLG TNF
32 positive regulation of tissue remodeling GO:0034105 9.59 IL18 IL2
33 regulation of isotype switching GO:0045191 9.58 IL10 IL4
34 regulation of regulatory T cell differentiation GO:0045589 9.58 IFNG IL2 IL2RA
35 receptor biosynthetic process GO:0032800 9.54 IL10 TNF
36 positive regulation of interleukin-17 production GO:0032740 9.54 IL18 IL2 NOD2
37 regulation of T cell homeostatic proliferation GO:0046013 9.52 IL2 IL2RA
38 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 IFNG TNF
39 cytokine-mediated signaling pathway GO:0019221 9.5 FASLG IL10 IL18 IL2 IL2RA IL4
40 positive regulation of vitamin D biosynthetic process GO:0060557 9.49 IFNG TNF
41 type 2 immune response GO:0042092 9.43 IL10 IL18 IL4
42 immune response GO:0006955 9.28 FASLG IFNG IL10 IL18 IL2 IL2RA
43 positive regulation of transcription by RNA polymerase II GO:0045944 10.12 IL10 IL18 IL2 IL4 NOD2 TNF

Molecular functions related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.77 ARHGAP45 FASLG GZMB IFNG IL10 IL18
2 cytokine activity GO:0005125 9.17 FASLG IFNG IL10 IL18 IL2 IL4

Sources for Acute Graft Versus Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....